Kidney cancer is the sixth most common cancer for men and the tenth most common cancer for women. Cancer.Net Associate Editor Brian Rini, MD, shares 4 things people need to know about kidney cancer.
Cancer.Net Associate Editors discuss exciting and practice-changing cancer research from ASCO Annual Meeting in this Research Round Up podcast.
Lung cancer affects tens of thousands of Americans every year. In this blog post, Cancer.Net Associate Editor Dr. Jyoti Patel describes 9 things every person should know about lung cancer.
ASCO Annual Meeting 2018: Less Treatment Needed for Some Patients With Breast Cancer and Kidney Cancer, Immunotherapy for Non-Small Cell Lung Cancer, and Maintenance Chemotherapy for Rhabdomyosarcoma
Oncology professionals from around the globe are at the 2018 ASCO Annual Meeting. Today’s key research highlights include new treatment options and improved survival for breast cancer, kidney cancer, non-small cell lung cancer, and rhabdomyosarcoma.
ASCO Annual Meeting 2018: New Insight Into Lynch Syndrome, Finding and Treating Lung Cancer, a New Targeted Therapy for Breast Cancer, and Evidence that Personalized Medicine Helps
Oncology professionals from around the globe are at the 2018 ASCO Annual Meeting. Today’s key research highlights address the connection between microsatellite instability and Lynch syndrome, a blood test that may be used to find early lung cancer, a new targeted therapy for treating advanced breast cancer, an immunotherapy-chemotherapy combination that slows lung cancer growth, and evidence that personalized medicine helps people with cancer live longer.
In this podcast, Dr. Gary Lyman describes biosimilars for cancer treatment and why they are important. He also talks about why ASCO is releasing a statement on them today.
ASCO and NCCN have worked together to help clinicians and patients identify and treat the side effects of immunotherapy before they become dangerous. Doctor and patient advocate Laura Porter describes what to watch out for if you’re taking an immune checkpoint inhibitor, a type of immunotherapy, for cancer.
The 2018 Genitourinary Cancers Symposium includes exciting research that focuses on effective treatment options for kidney cancer, prostate cancer, and bladder cancer.
The 2018 Clinical Cancer Advances report of the American Society of Clinical Oncology has crowned an adoptive cell immunotherapy as its Advance of the Year. What is this innovative cancer treatment? What are the risks and benefits?
“Even after I heard horror stories about the negative effects of indoor tanning, I knew they’d never happen to me. I couldn’t have been more wrong.” Ashley Drury shares her journey from tanning bed advocate to survivor of advanced melanoma.